还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

                               
登录/注册后可看大图

5 D0 M" f% I* L' R请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
  Q: @5 p' |$ n; x! G3 g

1 b4 U- J" r4 `$ n7 A8 ?Sub-category:
Molecular Targets
) O* G; `  _7 s2 P( L) d

; V+ ?/ S' A: A& ^$ K) M4 {Category:
9 Y( E6 `3 `/ \7 Q5 pTumor Biology
  S0 U# i8 V" c' ]
/ `4 r3 F) M; A. M: `- ]0 S& J) b
, }+ p' s1 z; y9 W' I$ oMeeting:
) F: M4 k& Z$ b5 J4 F" U2011 ASCO Annual Meeting
- p8 i% o% v2 }4 w4 Z. b
* W! d, C" l3 ~$ i; t' ~
Session Type and Session Title:
* D  |$ X3 p5 ^3 ZPoster Discussion Session, Tumor Biology

2 M+ l# V$ g, g/ j7 z/ Y" q- W
2 x/ b4 v3 f% o1 Z. eAbstract No:
10517
" M! c# c3 @  q. ]$ G
/ B. u$ ?6 z3 b: ]' Z
Citation:
J Clin Oncol 29: 2011 (suppl; abstr 10517)
( v" N0 k  l3 ^  e" |! X2 e; w

5 b- s* i7 b) PAuthor(s):
' ~) p( L2 \+ d7 p. }& x3 hJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
( H$ {4 [9 @( @, C5 c1 X: R% h
: m) e  m9 s2 l
0 Z' i4 {2 c1 Q( P0 k
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

1 H) q; q+ d1 _Abstract Disclosures
. n+ _2 S; y( [+ @  G. C
Abstract:


# N& e  l+ |" i  h* o% [5 p' \Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
8 V! N" z9 `' |* l; Y9 A2 T
! m6 i% `- d& }8 w% Z

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

9 T+ p' i* f1 [0 I$ f: v& h                               
登录/注册后可看大图

. ^7 \4 `$ ?5 n) n: O没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

$ V  f; g1 X$ }, D  Q化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

4 v0 Z8 C% P2 C( b$ n7 ~                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
" o5 C1 n) g* q2 D! EALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

9 c+ Q, d" f  {; a0 U现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊